Reata Pharmaceuticals, Inc.
Symbol: RETA
NASDAQ
172.36
USDTrhová cena dnes
-89.3629
Pomer P/E
0.0000
Pomer PEG
6.57B
MRK Cap
- 0.00%
Výnos DIV
Reata Pharmaceuticals, Inc. (RETA) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1474.56 | 387.5 | 590.3 | 818.1 | ||||||||||
balance-sheet.row.short-term-investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 16.95 | 0 | 0 | 22.2 | ||||||||||
balance-sheet.row.inventory | 8.65 | 0 | 0 | -22.2 | ||||||||||
balance-sheet.row.other-current-assets | 77.1 | 10.3 | 6.2 | 29.2 | ||||||||||
balance-sheet.row.total-current-assets | 1577.27 | 397.8 | 596.5 | 847.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 459.6 | 116.4 | 138.4 | 4.9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 17.44 | 0.3 | 0.2 | 5.3 | ||||||||||
balance-sheet.row.total-non-current-assets | 477.04 | 116.7 | 138.5 | 10.3 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 2054.3 | 514.5 | 735 | 857.6 | ||||||||||
balance-sheet.row.account-payables | 60.53 | 18.7 | 13.5 | 4.8 | ||||||||||
balance-sheet.row.short-term-debt | 13.07 | 2.2 | 3.1 | 87.5 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 534.25 | 117.3 | 136 | 0 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 4.7 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 131.23 | 38.1 | 35.7 | 22.3 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 1869.5 | 521.2 | 495 | 321 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 470.98 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.total-liab | 2158.86 | 580.2 | 549 | 440.2 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -6223.86 | -1567.5 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.18 | 1501.8 | 0 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 501.33 | 514.5 | -706.6 | -518.1 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 501.33 | - | - | - | ||||||||||
Total Investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 544.11 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.net-debt | 336.1 | 77.2 | -454.2 | -818.1 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -87.62 | -311.9 | -297.4 | -247.8 | ||||||||||
cash-flows.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
cash-flows.row.deferred-income-tax | -291.96 | 0 | 0 | 11.2 | ||||||||||
cash-flows.row.stock-based-compensation | 87.84 | 58.7 | 56.8 | 57.6 | ||||||||||
cash-flows.row.change-in-working-capital | 7.84 | 9.3 | -49.6 | -172.7 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | -13.28 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 11.97 | 5.2 | 8.7 | 2.9 | ||||||||||
cash-flows.row.other-working-capital | 9.16 | 4.1 | -58.3 | -175.6 | ||||||||||
cash-flows.row.other-non-cash-items | 34.44 | 38.5 | 53.3 | 28.1 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -248.34 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.acquisitions-net | 75 | 0 | 0 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -631.88 | -661.9 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 617.42 | 320 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 59.42 | -345.2 | -1.3 | -0.9 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -167.2 | ||||||||||
cash-flows.row.common-stock-issued | 222.73 | 0 | 333.3 | 333.3 | ||||||||||
cash-flows.row.common-stock-repurchased | 22.65 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -231.54 | 1.5 | -324.1 | 311 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 90.61 | 1.5 | 9.1 | 477.1 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 167.98 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -98.31 | -547.9 | -227.9 | 153.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 208.01 | 42.3 | 590.3 | 818.1 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 306.32 | 590.3 | 818.1 | 664.3 | ||||||||||
cash-flows.row.operating-cash-flow | -248.34 | -204.3 | -235.7 | -322.3 | ||||||||||
cash-flows.row.capital-expenditure | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.free-cash-flow | -249.46 | -207.5 | -237 | -323.3 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 24.39 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.cost-of-revenue | 0.85 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | 23.55 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 203.31 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 114.18 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.operating-expenses | 364.3 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 365.15 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.interest-income | 0 | 6 | 0.2 | 0 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.total-operating-expenses | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.ebitda-caps | -332.65 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -59.48 | -270.2 | -244.7 | -226.3 | ||||||||||
income-statement-row.row.income-before-tax | -87.68 | -311.9 | -297.8 | -270.2 | ||||||||||
income-statement-row.row.income-tax-expense | 0.25 | 0 | -0.5 | -22.5 | ||||||||||
income-statement-row.row.net-income | -80.06 | -311.9 | -297.4 | -247.8 |
Často kladené otázky
Čo je Reata Pharmaceuticals, Inc. (RETA) celkové aktíva?
Reata Pharmaceuticals, Inc. (RETA) celkové aktíva sú 514491000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 22941000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.965.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -6.010.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -3.282.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -2.438.
Aká je Reata Pharmaceuticals, Inc. (RETA) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -311901000.000.
Aký je celkový dlh firmy?
Celkový dlh je 119464000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 280250000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 48843000.000.